Accelerating Life- Changing Medicines

We are knowledgeable, confident and results-oriented experts who work with a sense of urgency to identify, acquire and accelerate development and delivery of transformative medicines for patients.

Recent News

ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones

Completed enrollment in izokibep Phase 3 trial in hidradenitis suppurativa and enrollment completion in Phase 2b/3 trial in uveitis expected this month; top line data for both tria...

ACELYRIN, INC. Announces Leadership Transition

Mina Kim appointed Chief Executive Officer and to Board of Directors ACELYRIN Founder Shao-Lee Lin, M.D., Ph.D., steps down as Chief Executive Officer Shephard (Shep) Mpofu, M.D.,...

ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024

LOS ANGELES, April 29, 2024 (GLOBE NEWSWIRE) -- ACELYRIN, INC. (Nasdaq: SLRN), a late-stage clinical biopharma company focused on accelerating the development and delivery of trans...

Icon1/3Icon
Acelyrin Test Tube Icon

Our Science

We are exploring innovative approaches in immunology where we have the opportunity to make a clinically meaningful difference for patients relative to standard of care.

Learn More
Acelyrin Team Icon

Meet Our Leadership

We are led by a team of veteran biopharma executives who bring exceptional track records of developing and commercializing transformative therapies.

Learn More

Courageous Caring

Guided by our key cultural value of Courageous Caring, and driven by a sense of urgency, we are building an innovative biopharma company that aims to invest in, develop and commercialize clinically meaningful therapies.

0+

Participants Dosed with Izokibep

0+

Dedicated Professionals

$0B+

Growth financing committed

0

Clinical-stage programs

We Care as Scientists, and We Care as People
Who We Are

We Care as Scientists, and We Care as People

We have the right blend of scientific, medical, operational and corporate experience to identify, develop and commercialize treatments with the potential to dramatically transform patients’ lives.
Our Story Arrow purple
Our Work

Accelerating Transformative Therapies

We are actively investigating the potential of izokibep and lonigutamab in diseases where differentiated inhibition of validated targets may help to address unmet patient needs.

Careers

Join a team that Courageously Cares

ACELYRIN is building a biopharma company with a corporate culture of Courageous Caring - placing patients first and embracing the concept that all of us together are better than any one of us alone. We strive to address the most basic human needs: to live a productive life free from disease.
Learn More Arrow purple
Join a team that Courageously Cares